Pub. Date : 2021 Dec 15
PMID : 34944919
11 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Ginkgolide B Regulates CDDP Chemoresistance in Oral Cancer via the Platelet-Activating Factor Receptor Pathway. | Ginkgolides | platelet activating factor receptor | Homo sapiens |
| 2 | Ginkgolide B Regulates CDDP Chemoresistance in Oral Cancer via the Platelet-Activating Factor Receptor Pathway. | Cisplatin | platelet activating factor receptor | Homo sapiens |
| 3 | The purpose of the current study was to elucidate the mechanism regulating cisplatin (CDDP) sensitivity through PAFR functions in oral squamous cell carcinoma (OSCC). | Cisplatin | platelet activating factor receptor | Homo sapiens |
| 4 | The purpose of the current study was to elucidate the mechanism regulating cisplatin (CDDP) sensitivity through PAFR functions in oral squamous cell carcinoma (OSCC). | Cisplatin | platelet activating factor receptor | Homo sapiens |
| 5 | We first analyzed the correlation between PAFR expression and CDDP sensitivity in seven OSCC-derived cell lines based upon cell viability assays. | Cisplatin | platelet activating factor receptor | Homo sapiens |
| 6 | In addition to conducting PAFR-knockdown (siPAFR) experiments, we found that ginkgolide B (GB), a specific inhibitor of PAFR, enhanced both CDDP chemosusceptibility and apoptosis. | ginkgolide B | platelet activating factor receptor | Homo sapiens |
| 7 | In addition to conducting PAFR-knockdown (siPAFR) experiments, we found that ginkgolide B (GB), a specific inhibitor of PAFR, enhanced both CDDP chemosusceptibility and apoptosis. | ginkgolide B | platelet activating factor receptor | Homo sapiens |
| 8 | In addition to conducting PAFR-knockdown (siPAFR) experiments, we found that ginkgolide B (GB), a specific inhibitor of PAFR, enhanced both CDDP chemosusceptibility and apoptosis. | Cisplatin | platelet activating factor receptor | Homo sapiens |
| 9 | We next evaluated the downstream signaling pathway of PAFR in siPAFR-treated cells and GB-treated cells after CDDP treatment. | sipafr | platelet activating factor receptor | Homo sapiens |
| 10 | We next evaluated the downstream signaling pathway of PAFR in siPAFR-treated cells and GB-treated cells after CDDP treatment. | Cisplatin | platelet activating factor receptor | Homo sapiens |
| 11 | These results suggest that PAFR is a therapeutic target for modulating CDDP sensitivity in OSCC cells. | Cisplatin | platelet activating factor receptor | Homo sapiens |